PDK1 and cancer: In tumors, aberrant PDK1 activation by enhanced production of PI(3,4,5)P3 due to mutations in PI3K or PTEN frequently coincidences with downregulation of mutation of LKB1 [13,14], resulting in a decreased activation of AMPK, further enhancing Akt/mTOR activation, and thus, cancer progression.